Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 373

1.

The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome.

Ricciardelli C, Bianco-Miotto T, Jindal S, Butler LM, Leung S, McNeil CM, O'Toole SA, Ebrahimie E, Millar EKA, Sakko AJ, Ruiz AI, Vowler SL, Huntsman DG, Birrell SN, Sutherland RL, Palmieri C, Hickey TE, Tilley WD.

Clin Cancer Res. 2018 May 15;24(10):2328-2341. doi: 10.1158/1078-0432.CCR-17-1199. Epub 2018 Mar 7.

PMID:
29514843
2.

An RCT to Facilitate Implementation of School Practices Known to Increase Physical Activity.

Sutherland RL, Nathan NK, Lubans DR, Cohen K, Davies LJ, Desmet C, Cohen J, McCarthy NJ, Butler P, Wiggers J, Wolfenden L.

Am J Prev Med. 2017 Dec;53(6):818-828. doi: 10.1016/j.amepre.2017.08.009. Epub 2017 Oct 16.

3.

The Physical Activity 4 Everyone Cluster Randomized Trial: 2-Year Outcomes of a School Physical Activity Intervention Among Adolescents.

Sutherland RL, Campbell EM, Lubans DR, Morgan PJ, Nathan NK, Wolfenden L, Okely AD, Gillham KE, Hollis JL, Oldmeadow CJ, Williams AJ, Davies LJ, Wiese JS, Bisquera A, Wiggers JH.

Am J Prev Med. 2016 Aug;51(2):195-205. doi: 10.1016/j.amepre.2016.02.020. Epub 2016 Apr 18.

4.

Genomic analyses identify molecular subtypes of pancreatic cancer.

Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, Nourse C, Murtaugh LC, Harliwong I, Idrisoglu S, Manning S, Nourbakhsh E, Wani S, Fink L, Holmes O, Chin V, Anderson MJ, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Xu Q, Wilson PJ, Cloonan N, Kassahn KS, Taylor D, Quek K, Robertson A, Pantano L, Mincarelli L, Sanchez LN, Evers L, Wu J, Pinese M, Cowley MJ, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chantrill LA, Mawson A, Humphris J, Chou A, Pajic M, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Lovell JA, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Moran-Jones K, Jamieson NB, Graham JS, Duthie F, Oien K, Hair J, Grützmann R, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Rusev B, Capelli P, Salvia R, Tortora G, Mukhopadhyay D, Petersen GM; Australian Pancreatic Cancer Genome Initiative, Munzy DM, Fisher WE, Karim SA, Eshleman JR, Hruban RH, Pilarsky C, Morton JP, Sansom OJ, Scarpa A, Musgrove EA, Bailey UM, Hofmann O, Sutherland RL, Wheeler DA, Gill AJ, Gibbs RA, Pearson JV, Waddell N, Biankin AV, Grimmond SM.

Nature. 2016 Mar 3;531(7592):47-52. doi: 10.1038/nature16965. Epub 2016 Feb 24.

PMID:
26909576
5.

Assessment of the School Nutrition Environment: A Study in Australian Primary School Canteens.

Yoong SL, Nathan NK, Wyse RJ, Preece SJ, Williams CM, Sutherland RL, Wiggers JH, Delaney TM, Wolfenden L.

Am J Prev Med. 2015 Aug;49(2):215-22. doi: 10.1016/j.amepre.2015.02.002. Epub 2015 Jun 16.

PMID:
26091931
6.

The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo.

Susanto JM, Colvin EK, Pinese M, Chang DK, Pajic M, Mawson A, Caldon CE, Musgrove EA, Henshall SM, Sutherland RL, Biankin AV, Scarlett CJ.

Int J Oncol. 2015 May;46(5):2223-30. doi: 10.3892/ijo.2015.2894. Epub 2015 Feb 16.

PMID:
25695794
7.

Haematopoietic stem cell induction by somite-derived endothelial cells controlled by meox1.

Nguyen PD, Hollway GE, Sonntag C, Miles LB, Hall TE, Berger S, Fernandez KJ, Gurevich DB, Cole NJ, Alaei S, Ramialison M, Sutherland RL, Polo JM, Lieschke GJ, Currie PD.

Nature. 2014 Aug 21;512(7514):314-8. doi: 10.1038/nature13678. Epub 2014 Aug 13.

PMID:
25119043
8.

Methylation-capture and Next-Generation Sequencing of free circulating DNA from human plasma.

Warton K, Lin V, Navin T, Armstrong NJ, Kaplan W, Ying K, Gloss B, Mangs H, Nair SS, Hacker NF, Sutherland RL, Clark SJ, Samimi G.

BMC Genomics. 2014 Jun 15;15:476. doi: 10.1186/1471-2164-15-476.

9.

Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways.

Zheng Y, Chow SO, Boernert K, Basel D, Mikuscheva A, Kim S, Fong-Yee C, Trivedi T, Buttgereit F, Sutherland RL, Dunstan CR, Zhou H, Seibel MJ.

J Bone Miner Res. 2014 Sep;29(9):1938-49. doi: 10.1002/jbmr.2231.

10.

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.

Kang J, Sergio CM, Sutherland RL, Musgrove EA.

BMC Cancer. 2014 Jan 20;14:32. doi: 10.1186/1471-2407-14-32.

11.

ZNF300P1 encodes a lincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancer.

Gloss B, Moran-Jones K, Lin V, Gonzalez M, Scurry J, Hacker NF, Sutherland RL, Clark SJ, Samimi G.

Mol Cancer. 2014 Jan 6;13:3. doi: 10.1186/1476-4598-13-3.

12.

Adjuvant chemotherapy in elderly patients with pancreatic cancer.

Nagrial AM, Chang DK, Nguyen NQ, Johns AL, Chantrill LA, Humphris JL, Chin VT, Samra JS, Gill AJ, Pajic M; Australian Pancreatic Cancer Genome Initiative, Pinese M, Colvin EK, Scarlett CJ, Chou A, Kench JG, Sutherland RL, Horvath LG, Biankin AV.

Br J Cancer. 2014 Jan 21;110(2):313-9. doi: 10.1038/bjc.2013.722. Epub 2013 Nov 21.

13.

Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells.

McCloy RA, Shelley EJ, Roberts CG, Boslem E, Biden TJ, Nicholson RI, Gee JM, Sutherland RL, Musgrove EA, Burgess A, Butt AJ.

Br J Cancer. 2013 Dec 10;109(12):3034-41. doi: 10.1038/bjc.2013.693. Epub 2013 Oct 31.

14.

Transcription factor ATF3 links host adaptive response to breast cancer metastasis.

Wolford CC, McConoughey SJ, Jalgaonkar SP, Leon M, Merchant AS, Dominick JL, Yin X, Chang Y, Zmuda EJ, O'Toole SA, Millar EK, Roller SL, Shapiro CL, Ostrowski MC, Sutherland RL, Hai T.

J Clin Invest. 2013 Jul;123(7):2893-906. doi: 10.1172/JCI64410. Epub 2013 Jun 10.

15.

Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.

Browne BC, Hochgräfe F, Wu J, Millar EK, Barraclough J, Stone A, McCloy RA, Lee CS, Roberts C, Ali NA, Boulghourjian A, Schmich F, Linding R, Farrow L, Gee JM, Nicholson RI, O'Toole SA, Sutherland RL, Musgrove EA, Butt AJ, Daly RJ.

FEBS J. 2013 Nov;280(21):5237-57. doi: 10.1111/febs.12441. Epub 2013 Aug 19.

16.

A novel method of bladder neck imbrication to improve early urinary continence following robotic-assisted radical prostatectomy.

Beattie K, Symons J, Chopra S, Yuen C, Savdie R, Thanigasalam R, Haynes AM, Matthews J, Brenner PC, Rasiah K, Sutherland RL, Stricker PD.

J Robot Surg. 2013 Jun;7(2):193-9. doi: 10.1007/s11701-012-0371-2. Epub 2012 Jul 26.

PMID:
27000912
17.

β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression.

Schade B, Lesurf R, Sanguin-Gendreau V, Bui T, Deblois G, O'Toole SA, Millar EK, Zardawi SJ, Lopez-Knowles E, Sutherland RL, Giguère V, Kahn M, Hallett M, Muller WJ.

Cancer Res. 2013 Jul 15;73(14):4474-87. doi: 10.1158/0008-5472.CAN-12-3925. Epub 2013 May 29.

18.

Outcomes of transperineal template-guided prostate biopsy in 409 patients.

Symons JL, Huo A, Yuen CL, Haynes AM, Matthews J, Sutherland RL, Brenner P, Stricker PD.

BJU Int. 2013 Sep;112(5):585-93. doi: 10.1111/j.1464-410X.2012.11657.x. Epub 2013 Apr 3.

19.

Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater.

Chang DK, Jamieson NB, Johns AL, Scarlett CJ, Pajic M, Chou A, Pinese M, Humphris JL, Jones MD, Toon C, Nagrial AM, Chantrill LA, Chin VT, Pinho AV, Rooman I, Cowley MJ, Wu J, Mead RS, Colvin EK, Samra JS, Corbo V, Bassi C, Falconi M, Lawlor RT, Crippa S, Sperandio N, Bersani S, Dickson EJ, Mohamed MA, Oien KA, Foulis AK, Musgrove EA, Sutherland RL, Kench JG, Carter CR, Gill AJ, Scarpa A, McKay CJ, Biankin AV.

J Clin Oncol. 2013 Apr 1;31(10):1348-56. doi: 10.1200/JCO.2012.46.8868. Epub 2013 Feb 25.

PMID:
23439753
20.

Sirtuin-1 regulates acinar-to-ductal metaplasia and supports cancer cell viability in pancreatic cancer.

Wauters E, Sanchez-Arévalo Lobo VJ, Pinho AV, Mawson A, Herranz D, Wu J, Cowley MJ, Colvin EK, Njicop EN, Sutherland RL, Liu T, Serrano M, Bouwens L, Real FX, Biankin AV, Rooman I.

Cancer Res. 2013 Apr 1;73(7):2357-67. doi: 10.1158/0008-5472.CAN-12-3359. Epub 2013 Jan 31.

21.

The role of the bone microenvironment in skeletal metastasis.

Zheng Y, Zhou H, Dunstan CR, Sutherland RL, Seibel MJ.

J Bone Oncol. 2012 Dec 11;2(1):47-57. doi: 10.1016/j.jbo.2012.11.002. eCollection 2013 Feb. Review.

22.

Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1.

Caldon CE, Sergio CM, Burgess A, Deans AJ, Sutherland RL, Musgrove EA.

Cell Cycle. 2013 Feb 15;12(4):606-17. doi: 10.4161/cc.23512. Epub 2013 Jan 16.

23.

Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells.

Caldon CE, Sergio CM, Sutherland RL, Musgrove EA.

Cell Cycle. 2013 Feb 15;12(4):596-605. doi: 10.4161/cc.23409. Epub 2013 Jan 16.

24.

ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.

Kalyuga M, Gallego-Ortega D, Lee HJ, Roden DL, Cowley MJ, Caldon CE, Stone A, Allerdice SL, Valdes-Mora F, Launchbury R, Statham AL, Armstrong N, Alles MC, Young A, Egger A, Au W, Piggin CL, Evans CJ, Ledger A, Brummer T, Oakes SR, Kaplan W, Gee JM, Nicholson RI, Sutherland RL, Swarbrick A, Naylor MJ, Clark SJ, Carroll JS, Ormandy CJ.

PLoS Biol. 2012;10(12):e1001461. doi: 10.1371/journal.pbio.1001461. Epub 2012 Dec 27.

25.

Regional activation of the cancer genome by long-range epigenetic remodeling.

Bert SA, Robinson MD, Strbenac D, Statham AL, Song JZ, Hulf T, Sutherland RL, Coolen MW, Stirzaker C, Clark SJ.

Cancer Cell. 2013 Jan 14;23(1):9-22. doi: 10.1016/j.ccr.2012.11.006. Epub 2012 Dec 13.

26.

High-dose rate brachytherapy compared with open radical prostatectomy for the treatment of high-risk prostate cancer: 10 year biochemical freedom from relapse.

Savdie R, Symons J, Spernat D, Yuen C, Pe Benito RA, Haynes AM, Matthews J, Rasiah KK, Jagavkar RS, Yu C, Fogarty G, Kattan MW, Brenner P, Sutherland RL, Stricker PD.

BJU Int. 2012 Dec;110 Suppl 4:71-6. doi: 10.1111/j.1464-410X.2012.11480.x.

27.

TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers.

Shields BJ, Wiede F, Gurzov EN, Wee K, Hauser C, Zhu HJ, Molloy TJ, O'Toole SA, Daly RJ, Sutherland RL, Mitchell CA, McLean CA, Tiganis T.

Mol Cell Biol. 2013 Feb;33(3):557-70. doi: 10.1128/MCB.01016-12. Epub 2012 Nov 19.

28.

Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX.

Coates AS, Millar EK, O'Toole SA, Molloy TJ, Viale G, Goldhirsch A, Regan MM, Gelber RD, Sun Z, Castiglione-Gertsch M, Gusterson B, Musgrove EA, Sutherland RL.

Breast Cancer Res. 2012 Nov 5;14(6):R143. doi: 10.1186/bcr3348.

29.

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.

Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N; Australian Pancreatic Cancer Genome Initiative, Kakkar N, Zhao F, Wu YQ, Wang M, Muzny DM, Fisher WE, Brunicardi FC, Hodges SE, Reid JG, Drummond J, Chang K, Han Y, Lewis LR, Dinh H, Buhay CJ, Beck T, Timms L, Sam M, Begley K, Brown A, Pai D, Panchal A, Buchner N, De Borja R, Denroche RE, Yung CK, Serra S, Onetto N, Mukhopadhyay D, Tsao MS, Shaw PA, Petersen GM, Gallinger S, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Capelli P, Corbo V, Scardoni M, Tortora G, Tempero MA, Mann KM, Jenkins NA, Perez-Mancera PA, Adams DJ, Largaespada DA, Wessels LF, Rust AG, Stein LD, Tuveson DA, Copeland NG, Musgrove EA, Scarpa A, Eshleman JR, Hudson TJ, Sutherland RL, Wheeler DA, Pearson JV, McPherson JD, Gibbs RA, Grimmond SM.

Nature. 2012 Nov 15;491(7424):399-405. doi: 10.1038/nature11547. Epub 2012 Oct 24.

30.

RON is not a prognostic marker for resectable pancreatic cancer.

Tactacan CM, Chang DK, Cowley MJ, Humphrey ES, Wu J, Gill AJ, Chou A, Nones K, Grimmond SM, Sutherland RL, Biankin AV, Daly RJ; Australian Pancreratic Genome Initiative.

BMC Cancer. 2012 Sep 7;12:395. doi: 10.1186/1471-2407-12-395.

31.

Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer.

Hulf T, Sibbritt T, Wiklund ED, Patterson K, Song JZ, Stirzaker C, Qu W, Nair S, Horvath LG, Armstrong NJ, Kench JG, Sutherland RL, Clark SJ.

Oncogene. 2013 Jun 6;32(23):2891-9. doi: 10.1038/onc.2012.300. Epub 2012 Aug 6.

PMID:
22869146
32.

Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.

Stone A, Valdés-Mora F, Gee JM, Farrow L, McClelland RA, Fiegl H, Dutkowski C, McCloy RA, Sutherland RL, Musgrove EA, Nicholson RI.

PLoS One. 2012;7(7):e40466. doi: 10.1371/journal.pone.0040466. Epub 2012 Jul 10.

33.

Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.

Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black MA, Miller LD, Gee JM, Nicholson RI, Sutherland RL, Print CG, Musgrove EA.

Mol Cancer Ther. 2012 Jul;11(7):1488-99. doi: 10.1158/1535-7163.MCT-11-0963. Epub 2012 May 7.

34.

Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics.

Stone A, Sutherland RL, Musgrove EA.

Crit Rev Oncog. 2012;17(2):175-98. Review.

PMID:
22471707
35.

The prognostic and predictive value of serum CA19.9 in pancreatic cancer.

Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, Colvin EK, Nagrial A, Chin VT, Chantrill LA, Samra JS, Gill AJ, Kench JG, Merrett ND, Das A, Musgrove EA, Sutherland RL, Biankin AV; NSW Pancreatic Cancer Network.

Ann Oncol. 2012 Jul;23(7):1713-22. doi: 10.1093/annonc/mdr561. Epub 2012 Jan 11.

36.

Retinoid signaling in pancreatic cancer, injury and regeneration.

Colvin EK, Susanto JM, Kench JG, Ong VN, Mawson A, Pinese M, Chang DK, Rooman I, O'Toole SA, Segara D, Musgrove EA, Sutherland RL, Apte MV, Scarlett CJ, Biankin AV.

PLoS One. 2011;6(12):e29075. doi: 10.1371/journal.pone.0029075. Epub 2011 Dec 29.

37.

TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma.

Samimi G, Ring BZ, Ross DT, Seitz RS, Sutherland RL, O'Brien PM, Hacker NF, Huh WK.

Cancer Epidemiol Biomarkers Prev. 2012 Feb;21(2):273-9. doi: 10.1158/1055-9965.EPI-11-0917. Epub 2011 Dec 22.

38.

Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers.

Gloss BS, Patterson KI, Barton CA, Gonzalez M, Scurry JP, Hacker NF, Sutherland RL, O'Brien PM, Clark SJ.

Cancer Lett. 2012 May 1;318(1):76-85. doi: 10.1016/j.canlet.2011.12.003. Epub 2011 Dec 9.

PMID:
22155104
39.

Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.

Montavon C, Gloss BS, Warton K, Barton CA, Statham AL, Scurry JP, Tabor B, Nguyen TV, Qu W, Samimi G, Hacker NF, Sutherland RL, Clark SJ, O'Brien PM.

Gynecol Oncol. 2012 Mar;124(3):582-8. doi: 10.1016/j.ygyno.2011.11.026. Epub 2011 Nov 22.

PMID:
22115852
40.

Synthesis and in vitro evaluation of analogues of avocado-produced toxin (+)-(R)-persin in human breast cancer cells.

Brooke DG, Shelley EJ, Roberts CG, Denny WA, Sutherland RL, Butt AJ.

Bioorg Med Chem. 2011 Dec 1;19(23):7033-43. doi: 10.1016/j.bmc.2011.10.006. Epub 2011 Oct 13.

PMID:
22044656
41.

Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction.

Scarlett CJ, Colvin EK, Pinese M, Chang DK, Morey AL, Musgrove EA, Pajic M, Apte M, Henshall SM, Sutherland RL, Kench JG, Biankin AV.

PLoS One. 2011;6(10):e26088. doi: 10.1371/journal.pone.0026088. Epub 2011 Oct 14.

42.

High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.

Savdie R, Horvath LG, Benito RP, Rasiah KK, Haynes AM, Chatfield M, Stricker PD, Turner JJ, Delprado W, Henshall SM, Sutherland RL, Kench JG.

BJU Int. 2012 Jun;109(12):1794-800. doi: 10.1111/j.1464-410X.2011.10572.x. Epub 2011 Oct 12.

43.

Cyclin D as a therapeutic target in cancer.

Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL.

Nat Rev Cancer. 2011 Jul 7;11(8):558-72. doi: 10.1038/nrc3090. Review.

PMID:
21734724
44.

Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53.

Millar EK, Graham PH, McNeil CM, Browne L, O'Toole SA, Boulghourjian A, Kearsley JH, Papadatos G, Delaney G, Fox C, Nasser E, Capp A, Sutherland RL.

Br J Cancer. 2011 Jul 12;105(2):272-80. doi: 10.1038/bjc.2011.228. Epub 2011 Jun 28.

45.

Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4.

Sutherland RL.

Breast Cancer Res. 2011 May 20;13(3):106. doi: 10.1186/bcr2878.

46.

Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer.

O'Toole SA, Machalek DA, Shearer RF, Millar EK, Nair R, Schofield P, McLeod D, Cooper CL, McNeil CM, McFarland A, Nguyen A, Ormandy CJ, Qiu MR, Rabinovich B, Martelotto LG, Vu D, Hannigan GE, Musgrove EA, Christ D, Sutherland RL, Watkins DN, Swarbrick A.

Cancer Res. 2011 Jun 1;71(11):4002-14. doi: 10.1158/0008-5472.CAN-10-3738.

47.

Pathways of chemotherapy resistance in castration-resistant prostate cancer.

Mahon KL, Henshall SM, Sutherland RL, Horvath LG.

Endocr Relat Cancer. 2011 Jul 4;18(4):R103-23. doi: 10.1530/ERC-10-0343. Print 2011 Aug. Review.

48.

Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers.

Yan M, Jene N, Byrne D, Millar EK, O'Toole SA, McNeil CM, Bates GJ, Harris AL, Banham AH, Sutherland RL, Fox SB.

Breast Cancer Res. 2011 Apr 26;13(2):R47. doi: 10.1186/bcr2869.

49.

Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes.

Pajic M, Scarlett CJ, Chang DK, Sutherland RL, Biankin AV.

Hum Genet. 2011 Jul;130(1):93-101. doi: 10.1007/s00439-011-0990-0. Epub 2011 Apr 23. Review.

PMID:
21516344
50.

Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer.

Yip PY, Kench JG, Rasiah KK, Benito RP, Lee CS, Stricker PD, Henshall SM, Sutherland RL, Horvath LG.

Prostate. 2011 Nov;71(15):1638-45. doi: 10.1002/pros.21381. Epub 2011 Mar 22.

PMID:
21432866

Supplemental Content

Loading ...
Support Center